aetherAI vs Caris Life Sciences
Caris sells a laboratory service and aetherAI sells software. Caris, founded in 2008 and listed on NASDAQ as CAI, runs tumor profiling, and its MI Cancer Seek page describes a sequencing assay on FFPE tissue approved by FDA under PMA P240010 in November 2024, with companion diagnostic claims for drugs such as Piqray and Vectibix. The vendor says ordering is integrated through EHRs at more than 3,100 locations without naming the systems, which fits a medical oncologist ordering a genomic profile. GPSai tissue-of-origin AI and FOLFIRSTai are listed under professional services, outside that approval.
aetherAI raised a Series B of NT$765M in 2024 led by CDIB Capital and listed on Taiwan's Emerging Stock Board on November 26, 2024. The viewer software and AI modules described on its About page suit a pathology lab going digital.
Pathology · Reviewed November 2, 2026
aetherAI
by aetherAI · founded 2015
FDA-cleared slide viewer for hospital pathology labs. Bone marrow and colon polyp AI modules are TFDA approved in Taiwan.
Caris Life Sciences
by Caris Life Sciences · founded 2008
FDA-approved MI Cancer Seek tumor profiling test for oncologists. The GPSai tissue-of-origin AI is a lab service outside that approval.
When to pick each one
aetherAI
- Series B of NT$765M in 2024, led by CDIB Capital
- Viewer software and AI modules for pathology labs
Caris Life Sciences
- FDA-approved MI Cancer Seek profiling, PMA P240010
- EHR ordering at 3,100+ locations, vendor claim
Score
Each row shows points earned of points available under the published rubric.
aetherAI
51of 100
Caris Life Sciences
65of 100
| Dimension | aetherAI | Caris Life Sciences | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 21 / 21 | -6.3 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 6 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
aetherAI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Caris Life Sciences
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
aetherAI
FDA decisions
K233126 (opens in new tab)510(k)2024-05-30
aetherSlide
Peer-reviewed
2 PubMed records name aetherAI.
Caris Life Sciences
FDA decisions
P240010 (opens in new tab)PMA2024-11-05
MI Cancer Seek
Peer-reviewed
5 PubMed records name Caris Life Sciences.
- An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins. (opens in new tab)
- Proactive identification of candidates for newly approved targeted therapies using a clinical decision support program. (opens in new tab)
- ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | aetherAI | Caris Life Sciences |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2015 | 2008 |
| HQ | TW | US |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.